Eli Lilly, Novo Nordisk close to cope with Trump on weight reduction drug costs
WASHINGTON — The Trump administration is nearing offers with Eli Lilly and Novo Nordisk to decrease the costs of their weight reduction medicine and develop entry to them, folks acquainted with the talks informed STAT.
The businesses have been near a deal for weeks, one lobbyist with data of the negotiations mentioned, echoing others who mentioned they consider the events are closing in on an settlement. The offers haven’t but been introduced, and the main points might nonetheless change.
The settlement is anticipated to incorporate Medicare protection of the medicine for weight reduction, the folks mentioned. Medicare has lined the injections to deal with diabetes and another circumstances, however to not assist folks shed pounds. The businesses would additionally conform to promote the medicine on to customers for lower than their record costs, a number of information shops reported.
This text is unique to STAT+ subscribers
Unlock this text — plus each day market-moving biopharma evaluation — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
